Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention
Recruitment status was: Recruiting
Plavix (clopidogrel) is a drug that is approved by the FDA (Food and Drug Administration) to reduce the risk of having another heart attack by preventing platelets (blood cells that are important in forming blood clots) from sticking together and forming another clot. Platelet activity can be measured by a machine called VerifyNow.
The purpose of this study is to see whether Hispanic women and White non-Hispanic women have the same platelet response to a commonly used drug, Plavix (clopidogrel). Recent studies have shown that platelets may be more active in Hispanics, making it more difficult to prevent clots from forming, even when using Plavix. In addition, studies have shown that women may also have more active platelets than men. There have been no studies of Hispanic women and the effect of Plavix on platelet activity.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Clopidogrel Resistance and Platelet Reactivity in Hispanic Females Undergoing Percutaneous Coronary Intervention|
- Platelet Reactivity measured by the VerifyNow P2Y12 Assay [ Time Frame: At least 14 days following the ACS event ] [ Designated as safety issue: No ]Compare the Hispanic female platelet reactivity response to the Caucasian female platelet reactivity response in females currently taking clopidogrel.
|Study Start Date:||January 2012|
|Estimated Study Completion Date:||October 2013|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01796873
|United States, Arizona|
|University of Arizona Medical Center South Campus|
|Tucson, Arizona, United States, 85713|
|University of Arizona Medical Center University Campus|
|Tucson, Arizona, United States, 85724|
|Principal Investigator:||Sasanka Jayasuriya, MD||University of Arizona|